Phase III CLL14: Venetoclax + Obinutuzumab vs Chlorambucil + Obinutuzumab in Patients With Previously Untreated CLL and Comorbidities

May 31 - June 4, 2019; Chicago, Illinois
Venetoclax/obinutuzumab produced significantly longer PFS and higher MRD negativity rates compared with chlorambucil/obinutuzumab in patients with previously untreated CLL and comorbidities.
Format: Microsoft PowerPoint (.ppt)
File Size: 246 KB
Released: June 10, 2019

Acknowledgements

Provided by the USF Health

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by educational grants from
Amgen
Celgene Corporation

Related Content

Downloadable slideset of FcRn pathway inhibition in patients with ITP, from Clinical Care Options (CCO)

David J. Kuter, MD, DPhil Released: July 23, 2021

Downloadable slideset of BTK inhibitors in patients with ITP, from Clinical Care Options (CCO)

David J. Kuter, MD, DPhil Released: July 23, 2021

Downloadable slideset of an expert’s overview of emerging therapies for patients with ITP, from Clinical Care Options (CCO)

David J. Kuter, MD, DPhil Released: July 23, 2021

Downloadable slideset of complement inhibition in patients with ITP, from Clinical Care Options (CCO)

person default Catherine M. Broome, MD Released: July 23, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue